当前，中国创新药产业正以强劲势头融入全球医药创新体系。从十年前以仿制药为主导，到如今在全球创新药商务合作拓展（BD）交易中占比显著提升，从“跟跑”“并跑”到在部分领域“领跑”，中国创新药凭借政策支持、临床突破与资本助力，实现了从“借船出海”到“造船出海”的跨越。在近日举行的第十届医药创新与投资大会上，《证券日报》记者对话多位医药行业领军人物，解码中国创新药在全球格局重塑中的突围路径与远航方向。多...
Source Link当前，中国创新药产业正以强劲势头融入全球医药创新体系。从十年前以仿制药为主导，到如今在全球创新药商务合作拓展（BD）交易中占比显著提升，从“跟跑”“并跑”到在部分领域“领跑”，中国创新药凭借政策支持、临床突破与资本助力，实现了从“借船出海”到“造船出海”的跨越。在近日举行的第十届医药创新与投资大会上，《证券日报》记者对话多位医药行业领军人物，解码中国创新药在全球格局重塑中的突围路径与远航方向。多...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.